(19)
(11)EP 3 612 236 A1

(12)

(43)Date of publication:
26.02.2020 Bulletin 2020/09

(21)Application number: 18719542.5

(22)Date of filing:  20.04.2018
(51)International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61K 45/06(2006.01)
A61P 35/02(2006.01)
A61K 31/7068(2006.01)
A61P 35/00(2006.01)
(86)International application number:
PCT/EP2018/060214
(87)International publication number:
WO 2018/193104 (25.10.2018 Gazette  2018/43)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30)Priority: 20.04.2017 GB 201706252
20.04.2017 GB 201706251
20.04.2017 GB 201706250
20.04.2017 GB 201706249
20.04.2017 GB 201706248
20.04.2017 GB 201706247
20.04.2017 GB 201706246
20.04.2017 GB 201706245
29.03.2018 GB 201805189

(71)Applicants:
  • ADC Therapeutics SA
    1066 Epalinges (CH)
  • Medimmune Limited
    Cambridge, Cambridgeshire CB21 6GH (GB)

(72)Inventors:
  • VAN BERKEL, Patricius Hendrikus Cornelis
    1066 Epalinges (CH)
  • SKELTON, Lisa
    1066 Epalinges (CH)
  • ZAMMARCHI, Francesca
    1066 Epalinges (CH)
  • FEINGOLD, Jay Marshall
    Murray Hill New Jersey 07947 (US)
  • WUERTHNER, Jens
    1066 Epalinges (CH)
  • HARTLEY, John
    London WC1E 6BT (GB)

(74)Representative: Mewburn Ellis LLP 
City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)

  


(54)COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE